Jeff Yass’s Design Therapeutics DSGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$480K Buy
38,149
+22,499
+144% +$311K ﹤0.01% 9854
2026
Q2
$226K Buy
+15,650
New +$195K ﹤0.01% 11682
2026
Q1
– Sell
-61,852
Closed -$580K – 13359
2025
Q4
$580K Buy
61,852
+47,829
+341% +$375K ﹤0.01% 8445
2025
Q3
$106K Sell
14,023
-24,147
-63% -$121K ﹤0.01% 11539
2025
Q2
$129K Sell
38,170
-5,053
-12% -$18.9K ﹤0.01% 11617
2025
Q1
$167K Buy
43,223
+5,911
+16% +$28.2K ﹤0.01% 11121
2024
Q4
$230K Buy
+37,312
New +$216K ﹤0.01% 10403
2024
Q3
– Sell
-21,726
Closed -$102K – 12190
2024
Q2
$72.8K Buy
21,726
+10,494
+93% +$40.9K ﹤0.01% 11224
2024
Q1
$45.3K Sell
11,232
-9,664
-46% -$25.8K ﹤0.01% 11590
2023
Q4
$55.4K Sell
20,896
-1,641
-7% -$3.76K ﹤0.01% 11676
2023
Q3
$53.2K Sell
22,537
-34,257
-60% -$160K ﹤0.01% 11274
2023
Q2
$358K Sell
56,794
-247,275
-81% -$1.51M ﹤0.01% 9079
2023
Q1
$1.75M Buy
304,069
+279,613
+1,143% +$2.09M ﹤0.01% 5432
2022
Q4
$251K Buy
24,456
+6,140
+34% +$83.2K ﹤0.01% 9539
2022
Q3
$306K Sell
18,316
-5,588
-23% -$111K ﹤0.01% 9743
2022
Q2
$335K Buy
+23,904
New +$323K ﹤0.01% 9268

Other funds holding DSGN

Jeff Yass's DSGN Position: Q3 2026 in Review

Jeff Yass increased its Design Therapeutics (DSGN) stake by 144% in Q3 2026, buying an estimated $311K and bringing the position to 38,149 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #9854.

Jeff Yass first reported a position in DSGN in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.75M in Q1 2023. 140 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • Jeff Yass held 38,149 shares of Design Therapeutics worth $480K as of Q3 2026.
  • Jeff Yass bought 22,499 Design Therapeutics shares in Q3 2026, an estimated $311K.
  • Design Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #9854 holding.
  • Jeff Yass first reported a position in Design Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • Jeff Yass's Design Therapeutics position peaked at $1.75M in Q1 2023.
  • 140 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.